Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
1998-01-09
2008-03-11
Brumback, Brenda (Department: 1654)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093100, C424S093210, C435S366000
Reexamination Certificate
active
07341719
ABSTRACT:
Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells. Endogenous biochemical(s) are used to control cell fusion of myoblasts among themselves or with other cell types. An automated cell processor within a cell bank which enables the manufacture, at a single run, of unprecedented large quantities (greater than 100 billion) of normal or genotypically or phenotypically altered myogenic cells is also disclosed.
REFERENCES:
patent: 4154652 (1979-05-01), Sawamura et al.
patent: 4542143 (1985-09-01), Hosokawa et al.
patent: 5139481 (1992-08-01), Faustman et al.
patent: 93/17697 (1993-09-01), None
patent: 95/14079 (1995-05-01), None
patent: 96/38544 (1996-12-01), None
Coovert et al., Current Opinion in Neurology 7:463-470, 1994.
DiMario et al., Neuromuscular Development and Disease, Kelly et al. ed., Raven Press, Ltd., New York, 1992.
Hoffman, Cell Transplantation 2:49-57, 1993.
Morgan et al., Journal of Cell Science 102:779-787, 1992.
Morgan, “Cell and Gene Therapy in Duchenne Muscular Dystrophy”, Human Gene Therapy, vol. 5, pp. 165-173, (1994).
Maltsev et al., “Embryonic Stem Cells Differentiate in vitro into Cardiomyocytes Representing Sinusnodal, Atrial and Ventricular Cell Types”, Mech. Devl., vol. 44, pp. 41-50, (1993).
Koh et al., “Long-term Survival of AT-1 Cardiomyocyte Grafts in Syngeneic Myocardium”, Am. J. Physiol, vol. 264, pp. 1727-1733, (1993).
Watson et al., “Working Toward Human Gene Therapy: Recombinant DNA”, New York, W.H. Freeman & Co., pp. 576, (1992).
Entrikin et al., Drugs in Muscular Dystrophy of the Chicken: Corticosterone-21 Acetate; Nerve & Muscle, (1984).
C.A. Bonsett, Duchenne Muscular Dystrophy-A Rational Approach to Disease Comprehension and Therapy, Indiana Medicine, Mar., 1986.
Lee et al., “Mdx Transgenic Mouse: Restoration of Recombinant Dystrophin to the Dystrophic Muscle”, Human Gene Therapy, (1993).
Rowland, “Prednisone in Duchenne Muscular Dystrophy”, The Lancet, Feb. 15, 1975.
Wolfe et al., “Direct Gene Transfer into Mouse Muscle in Vivo”, Science, vol. 274, pp. 1465-1468, (1990).
Folkers et al., “Treatment of Preclinical Muscular Dystrophy with Coenzyme Q”, Excerpta Med. Int. Service, vol. 334, p. 158, (1974).
Law, “Reduced Regenerative Capability of Dystrophic Mouse Muscle”, Exp. Neurol, vol. 60, pp. 231-243, (1978).
Young et al., “Histochemical Analysis of Newly Synthesized and Accumulated Sulfated Glycosaminoglycans During Musculogensis in the Embryonic Chic Leg.”, J. Morph, vol. 201, pp. 85-103, (1989).
Jackman et al., “Catheter Recordings of Accessory Atrioventricular Pathway Activation . . . ” From Cell to Bedside, pp. 491-502, (1990).
Soonpaa et al., “Formation of Nascent Intercalated Disks Between Grafted Fetal Cardiomyocytes and Host Myocardium”, Science, pp. 264-298, (1994).
Huard et al., “Human Myoblast Transplantation in Immunodeficient and Immunosuppressed Mice: Evidence of Rejection Muscle Nerve”, vol. 17, pp. 224-234, (1994).
Roy et al., “Antibody Formation After Myoblast Transplantation in Duchenne-Dystrophic Patients, Donor HLA Compatible”, Transpl. Proc., vol. 25, pp. 995-997, (1993).
Huard et al., “Human Myoblast Transplantation Between Immunohistocompatible Donors and Recipients Produces Immune Reactions”, Transpl. Proc., vol. 24, pp. 3049-3051, (1992).
Law et al., “Pathogenesis and Treatment of Hereditary Muscular Dystrophy”, Kakulas BA, Mastalgia, pp. 101-118, (1990).
Law et al., “Myoblast Injection Method Regulates Cell Distribution and Fusion”, Transpl. Proc. in Press.
Law et al., “New Muscle Transplant Method Produces Normal Twitch Tension in Dystrophic Muscle”, Nerve, vol. 2, pp. 356-363.
Law et al., “Feasibility, Safety, and Efficacy of Myoblast Transfer Therapy on Duchenne Muscular Dystrophy Boys”, Cell Transplantation, vol. 1, pp. 235-244, (1992).
Law et al., “Cell Transplantation as an Experimental Treatment for Duchenne Muscular Dystrophy”, Cell Transplantation, vol. 3, pp. 485-503, (1993).
Peterson, “Chimaera Mouse Study Shows absence of Disease in Genetically Dystrophic Muscle”, Nature, vol. 248, pp. 561-564, (1974).
Cox et al., “Overexpression of Dystrophin in Transgenic MDX Mice Eliminates Dystrophic Symptoms Without Toxicity”, Nature, vol. 364, pp. 725-729, (1993).
Milhorat, “Therapy in Muscular Dystrophy Medical Annals of the District of Columbia”, vol. 23, pp. 15, (1954).
Wood, “New Therapeutic Directions in Duchenne Muscular Dystrophy Following Discovery of Dystrophin”, Pathogenesis and Therapy of Duchenne and Becker, Muscular Dystrophy, Raven Press, pp. 85-99.
Annals of the District of Columbia vol. 23, pp. 15, (1954).
Van Meter, “Progressive Muscular Dystrophy”, Calif. Med., vol. 79, pp. 297-299, (1990).
Nakahara, “Studies on Progressive Muscular Dystrophy”, Arzneim. Forsch., vol. 15, pp. 591-595, (1965).
Drachman et al., “Prednisone in Duchenne Muscular Dystrophy”, Lancet, vol. 2, pp. 1409-1412, (1974).
Coakley et al., “Mazindol in Duchenne Muscular Dystrophy”, Lancet, vol. 1, No. 8578, pp. 184, (1988).
Munsat et al., “Prednisone in Duchenne Muscular Dystrophy”, Lancet, vol. 1, pp. 276-277, (1975).
Siegel et al., “Failure of Corticosteroid in the Treatment of Duchenne (Pseudo-Hypertrophic) Muscular Dystrophy”, I.M.J., vol. 145, pp. 32-33, (1974).
Acsadi et al., “Human Dystrophin Expression in MDX Mice After Intramuscular Injection of DNA Constructs”, Nature, vol. 352, pp. 815-818, (1991).
Neumeyer et al., “Arterial Delivery of Myoblasts to Skeletal Muscle”, Neurology, vol. 42, pp. 2258-2262, (1992).
Smith et al., “Genes Transferred by Retroviral Vectors into Normal and Mutant Myoblasts in Primary Cultures Are Expressed in Myotubes”, Mol. & Cell. Biol., vol. 10, pp. 3268-3271, (1990).
Hyde et al., “Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy”, Nature, vol. 362, pp. 250-255, (1993).
Hoffman et al., “Dystrophin: The Protein Product of the Duchenne Muscular Dystrophy”, Locus. Cell, vol. 51, pp. 919-928, (1987).
Chen et al., “Dystrophin Cytochemistry in MDX Mouse Muscles Injected with Labeled Normal Myoblasts”, Cell Transplantation, vol. 1, pp. 17-22, (1992).
Partridge et al., “Conversion of MDX Myofibers From Dystrophin-Negative to Positive by Injection of Normal Myoblasts”, Nature, vol. 337, pp. 116-117, (1989).
Gussioni et al., “Normal Dystrophin Transcripts Detected in Duchenne Muscular Dystrophy Patients After Myoblast Transplantation”, Nature, vol. 365, pp. 435-438, (1992).
Huard et al., “Myoblast Transplantation Produced Dystrophin-Positive Muscle Fibers in a 16-Year Old Patient with Duchenne Muscular Dystrophy”, Clin. Sci., vol. 81, pp. 287-288, (1991).
Huard et al., “Human Myoblast Transplantation: Preliminary
Brumback Brenda
Heller Ehrman White & McAuliffe LLP
LandOfFree
Myoblast therapy for cosmetic treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Myoblast therapy for cosmetic treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myoblast therapy for cosmetic treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981024